Ahead of sec­ond FDA chance, CorMedix winds down Eu­ro­pean busi­ness

The bear mar­ket struck again Thurs­day morn­ing as a New Jer­sey-based an­ti­fun­gal biotech re­port­ed a sig­nif­i­cant shift in op­er­a­tions.

CorMedix will be shak­ing up much of its C-suite and halt­ing op­er­a­tions in Eu­rope, the com­pa­ny an­nounced, as it looks to re­bound from a March 2021 CRL. The com­pa­ny had re-filed its ap­pli­ca­tion about six weeks ago but the changes high­light the new di­rec­tion as it pre­pares to meet the FDA once again.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER